Answers are grounded in this paper and cite their sources.
The past 20 years have brought several important advances in the management of multiple sclerosis (MS). Magnetic resonance imaging (MRI) has given us a window into this disease and has transformed the diagnostic process, allowing it to be made much earlier. It has also been established that immunomodulation can prevent demyelinating events in relapsing remitting MS (RRMS). These developments impact on primary care because there is increasing evidence that early diagnosis and treatment of MS may delay, or even prevent the previously inevitable disability. 1 At the other end of the spectrum, people with MS with disability are increasingly being managed in the community away from secondary care. The National Institute for Health and Care Excellence (NICE) has recently published an updated guideline for MS patient care. This article highlights the new developments and NICE guidance.
No takes yet. Share an insight, caveat, or question.
Dimitrov et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: